Lava M, Schüpbach-Regula G, Steiner A, Meylan M
Clinic for Ruminants, Vetsuisse-Faculty, University of Berne, Switzerland.
Veterinary Public Health Institute, Vetsuisse-Faculty, University of Berne, Switzerland.
Prev Vet Med. 2016 Apr 1;126:121-30. doi: 10.1016/j.prevetmed.2016.02.002. Epub 2016 Feb 5.
Ninety-one Swiss veal farms producing under a label with improved welfare standards were visited between August and December 2014 to investigate risk factors related to antimicrobial drug use and mortality. All herds consisted of own and purchased calves, with a median of 77.4% of purchased calves. The calves' mean age was 29±15days at purchasing and the fattening period lasted at average 120±28 days. The mean carcass weight was 125±12kg. A mean of 58±33 calves were fattened per farm and year, and purchased calves were bought from a mean of 20±17 farms of origin. Antimicrobial drug treatment incidence was calculated with the defined daily dose methodology. The mean treatment incidence (TIADD) was 21±15 daily doses per calf and year. The mean mortality risk was 4.1%, calves died at a mean age of 94±50 days, and the main causes of death were bovine respiratory disease (BRD, 50%) and gastro-intestinal disease (33%). Two multivariable models were constructed, for antimicrobial drug treatment incidence (53 farms) and mortality (91 farms). No quarantine, shared air space for several groups of calves, and no clinical examination upon arrival at the farm were associated with increased antimicrobial treatment incidence. Maximum group size and weight differences >100kg within a group were associated with increased mortality risk, while vaccination and beef breed were associated with decreased mortality risk. The majority of antimicrobial treatments (84.6%) were given as group treatments with oral powder fed through an automatic milk feeding system. Combination products containing chlortetracycline with tylosin and sulfadimidine or with spiramycin were used for 54.9%, and amoxicillin for 43.7% of the oral group treatments. The main indication for individual treatment was BRD (73%). The mean age at the time of treatment was 51 days, corresponding to an estimated weight of 80-100kg. Individual treatments were mainly applied through injections (88.5%), and included administration of fluoroquinolones in 38.3%, penicillines (amoxicillin or benzylpenicillin) in 25.6%, macrolides in 13.1%, tetracyclines in 12.0%, 3th and 4th generation cephalosporines in 4.7%, and florfenicol in 3.9% of the cases. The present study allowed for identifying risk factors for increased antimicrobial drug treatment and mortality. This is an important basis for future studies aiming at reducing treatment incidence and mortality in veal farms. Our results indicate that improvement is needed in the selection of drugs for the treatment of veal calves according to the principles of prudent use of antibiotics.
2014年8月至12月期间,对91家采用福利标准有所改善的标签生产的瑞士小牛肉养殖场进行了走访,以调查与抗菌药物使用和死亡率相关的风险因素。所有牛群均由自有和购买的犊牛组成,购买的犊牛中位数占77.4%。犊牛购买时的平均年龄为29±15天,育肥期平均持续120±28天。胴体平均重量为125±12千克。每个农场每年平均育肥58±33头犊牛,购买的犊牛平均来自20±17个原产农场。采用限定日剂量方法计算抗菌药物治疗发生率。平均治疗发生率(TIADD)为每头犊牛每年21±15个限定日剂量。平均死亡风险为4.1%,犊牛死亡时的平均年龄为94±50天,主要死亡原因是牛呼吸道疾病(BRD,50%)和胃肠道疾病(33%)。构建了两个多变量模型,分别针对抗菌药物治疗发生率(53个农场)和死亡率(91个农场)。没有检疫、多组犊牛共用空气空间以及犊牛到达农场时没有进行临床检查与抗菌治疗发生率增加有关。最大组群规模和组内体重差异>100千克与死亡风险增加有关,而疫苗接种和肉牛品种与死亡风险降低有关。大多数抗菌治疗(84.6%)是以通过自动喂奶系统投喂口服粉剂的方式进行群体治疗。含有金霉素与泰乐菌素和磺胺二甲嘧啶或与螺旋霉素的复方产品用于54.9%的口服群体治疗,阿莫西林用于43.7%的口服群体治疗。个体治疗的主要指征是BRD(73%)。治疗时的平均年龄为51天,对应估计体重为80 - 100千克。个体治疗主要通过注射进行(88.5%),其中38.3%的病例使用氟喹诺酮类药物,25.6%使用青霉素类(阿莫西林或苄星青霉素),13.1%使用大环内酯类,12.0%使用四环素类,4.7%使用第三代和第四代头孢菌素类,3.9%使用氟苯尼考。本研究有助于识别抗菌药物治疗增加和死亡率上升的风险因素。这是未来旨在降低小牛肉养殖场治疗发生率和死亡率研究的重要基础。我们的结果表明,需要根据谨慎使用抗生素的原则改进小牛肉犊治疗药物的选择。